A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer (NCT01567891).Kunle Odunsi, Rafael G. Amado, Erin Van Winkle et al.|Journal of Clinical Oncology|2017Cited by 10
ALL-026: Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II StudyMichael W. Boyer, Jennifer Willert, Sonali Chaudhury et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 1
Poster: ALL-026: Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion Following Loss of B-Cell Aplasia in Pediatric and Young Adult Patients with Acute Lymphoblastic Leukemia: HESTER Phase II StudyMichael W. Boyer, Jennifer Willert, Sonali Chaudhury et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 0